Delytact (teserpaturev) is a genetically engineered oncolytic herpes simplex virus type 1 (HSV-1) that was approved for marketing in Japan earlier this year, and received pricing approval in ...

Find out more about the overall breast cancer treatment landscape, as biotech companies make progress with different ...

Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat ...

3月20日，浙江大学科研团队在国际顶级刊物Nature（《自然》）上又发表了两项重磅科研成果。浙江大学光电科学与工程学院/海宁国际联合学院狄大卫教授和赵保丹研究员团队研发的微米和纳米钙钛矿LED（micro-PeLED和nano-PeLED）达到了传 ...

It's not the first therapy in the oncolytic virus class to be approved around the world, as that accolade went to Amgen's Imlygic (talimogene laherparepvec), which was cleared by the FDA for the ...

A bacterium makes a molecule that kills drug-resistant fungi in an unusual way — by targeting various phospholipid molecules ...

RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and Calidi Biotherapeutics, Inc. (NYSE American:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program ...

CG Oncology (NASDAQ:CGON – Get Free Report) is projected to post its quarterly earnings results before the market opens on Tuesday, March 25th. Analysts expect CG Oncology to post earnings of ($0.37) ...

溶瘤细菌的作用机制独特而精妙。当它们定位到肿瘤微环境后，不仅能够特异性地在肿瘤内部大量繁殖，诱导肿瘤细胞死亡，还能充当载体，递送药物及免疫刺激分子，从多个维度对抗肿瘤。那接下来，就让我们以全球首创的溶瘤细菌载体产品—— 上海缮维特生物技术有限公司研发 ...

Stem cell therapy has emerged as a groundbreaking treatment option for corneal injuries, offering hope to individuals ...